Loading...
Loading...
ASLN| Name | Value |
|---|---|
| Revenues | 12.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 12.0M |
| Operating Expense | 14.4M |
| Operating I/L | -2.4M |
| Other Income/Expense | 1.6M |
| Interest Income | 0.1M |
| Pretax | -1.8M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -1.9M |
ASLAN Pharmaceuticals Limited is a clinical-stage biopharmaceutical company specializing in immunology treatments. The company's clinical portfolio includes ASLAN004, a monoclonal therapy for atopic dermatitis and other immunology indications, and ASLAN003, a small-molecule inhibitor for autoimmune conditions. ASLAN has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics targeting the AhR pathway. Partnerships with Almirall, Array BioPharma, and CSL Limited further enhance its product offerings.
